Status:
COMPLETED
Study of M5049 in Healthy Japanese and Caucasian Participants
Lead Sponsor:
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Conditions:
Healthy
Eligibility:
All Genders
20-55 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to evaluate and determine the safety, tolerability and pharmacokinetics of single-doses of M5049 up to 3 dose levels administered as film-coated tablet under fasted condit...
Eligibility Criteria
Inclusion
- Japanese participants must be first generation (born in Japan) with both biological parents and all 4 biological grandparents being Japanese native born. Caucasian participants must have both biological parents and 4 biological grandparents of Caucasian descent
- Overtly healthy participants as determined by medical evaluation, including medical history, physical examination, laboratory tests, and cardiac monitoring (blood pressure, heart rate and 12-Lead resting ECG)
- Participants with body weight within 45 to 90 kilograms (kg) (female) and 55 to 90 kg (male) and body mass index (BMI) between 18.5 and 29.9 kilograms per meter square (kg/m\^2)
- A Caucasian participant will be matched by body weight (± 20% body weight \[kg\]), height (± 15% height \[centimeter (cm) \]) and sex to each Japanese participant
- Other protocol defined inclusion criteria could apply
Exclusion
- Participants with history of clinically relevant disease of any organ system that may interfere with the objectives of the study or provide a risk to the health of the participant
- Participants with history of relevant drug hypersensitivity
- Participants with history of splenectomy, epilepsy, other neurological disorders or neuropsychiatric conditions
- Participants with history of a tuberculosis and positive Screening test for hepatitis B surface antigen
- Participants with history of alcoholism or drug abuse
- Other protocol defined exclusion criteria could apply
Key Trial Info
Start Date :
May 6 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 23 2021
Estimated Enrollment :
36 Patients enrolled
Trial Details
Trial ID
NCT04880213
Start Date
May 6 2021
End Date
November 23 2021
Last Update
April 6 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Covance Clinical Research Unit Ltd.
Leeds, United Kingdom